Cardiovascular Risk Management in Diabetes: A Cross-Specialty Approach to the Clinical Challenges CME/CE

Burton E. Sobel, MD, Chairman; Patrick J. Boyle, MD; William T. Cefalu, MD Author Information and Disclosures

Release Date: May 23, 2008; Valid for credit through May 23, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.0 ANCC contact hours

This CE/CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Cardiovascular Risk Management in Diabetes: A Cross-Specialty Approach to the Clinical Challenges" symposium held in Chicago, Illinois, on March 31, 2008.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 CME Consultants
Takeda
Learning Objectives
Upon completion of this activity, participants should be able to:
  1. State the mechanisms through which insulin resistance and hyperglycemia contribute to cardiovascular risk in patients with diabetes.
  2. Describe the mechanisms of action of interventions used for glycemic control in patients with diabetes and how achieving goal can improve outcomes.
  3. Discuss the management of cardiovascular risk in patients with diabetes and the likely response to interventions.
  4. Review the cardiovascular effects of the interventions used in patients with diabetes.
  5. Consider how management recommendations can improve outcomes in patients with diabetes.
Author Disclosures
Patrick J. Boyle, MD
Disclosure: Advisory Board/Speaker Honoraria: Takeda Pharmaceuticals North America

William T. Cefalu, MD
Disclosure: Grant/Research Support: Amylin, Lilly; Consultant: Merck, Pfizer

Speaker Honoraria: Amylin, Lilly, Merck, Pfizer

Burton E. Sobel, MD
Disclosure: Director: Ariad Pharmaceuticals, Inc., Clinical Data, Inc., Interxon Corp., Nuvelo, Inc.
 
CME Consultants, Inc.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME Consultants and Strategic Consultants International. CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.

CME Consultants designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

CME Consultants is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CME Consultants designates this program for 1.0 contact hours. Participants should claim only those contact hours actual spent in the education activity.

In order to receive credit for this activity, each participant must complete the evaluation form and certificate request form. Certificates will be mailed to activity participants in approximately 4 to 6 weeks after receipt of the completed evaluation and certificate request form.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.